Low rates of preventive practices in patients with peripheral vascular disease

Canadian Journal of Cardiology

Volumn 15, Issue 11, 1999, Pages 1259-1263

  Anand, Sonia S ^a,b   Kundi, Anjali ^a   Eikelboom, John ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HGH McMaster Clinic   (Canada)

Author keywords

Peripheral vascular disease; Prevention; Risk factors; Vasculature

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYPOCHOLESTEROLEMIC AGENT; WARFARIN;

ADULT; AGED; ARTERY BYPASS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY;

AGED; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; ONTARIO; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PREVENTIVE MEDICINE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 0033404976     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1982;211:249-56.
2. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-49.
3. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-5.
4. Dagenais GR, Maurice S, Robitaille NM, Gingras S, Lupien PJ. Intermittent claudication in Quebec men from 1974-1986: the Quebec Cardiovascular Study. Clin Invest Med 1991;14:93-100.
5. Clagett GP. Antithrombotic therapy for lower extremity bypass. J Vasc Surg 1992;15:873-5.
6. Collaborative overview of randomised trials of antiplatelet therapy -I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
7. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;ii:57-66.
8. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. BMJ 1986;293:1137-40.
9. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989;30:50-7.
10. Farkouh ME, Rihal CS, Gersh BJ, et al. Influence of coronary heart disease on morbidity and mortality after lower extremity revascularization surgery: a population based study in Olmsted County, Minnesota (1970-1987). J Am Coll Cardiol 1994;24:1290-6.
11. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
13. Tsuyuki RT, Teo KK, Ikuta RM, et al. Mortality risk and patterns of practice in 2,070 patients with acute myocardial infarction, 1987-92. Relative importance of age, sex. and medical therapy. Chest 1994;105:1687-92.
14. Tu J, Austin P, Rochon P, Zhang H. Secondary prevention after acute myocardial infarction, congestive heart failure and coronary artery bypass graft surgery in Ontario. In: Naylor CD, Slaughter PM, eds. Cardiovascular Health & Services in Ontario: An ICES Atlas. Toronto: Institute for Clinical Evaluative Sciences, 1999:199-237.
15. Montague T, Taylor L, Martin S, et al. Can practice patterns and outcomes be successfully altered? Examples from cardiovascular medicine. The Clinical Quality Improvement Network (CQIN) Investigators. Can J Cardiol 1995;11:487-92.